This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BG00010, NsG1, Artemin, Enovin
Description: Neublastin is a novel therapeutic protein for the treatment of neuropathic pain. Neublastin can influence the survival and function of peripheral sensory neurons. Neublastin is a member of the GDNF family of neurotrophic factors. The molecule is also known as Artemin and Enovin in the scientific literature. The utility of Neublastin for the treatment of neuropathy and associated pain has been demonstrated in animal models.
Deal Structure: In August 2010, NsGene announced that Biogen Idec and NsGene executed a new and expanded agreement, which grants Biogen Idec exclusive global rights to commercialise Neublastin for all indications, and in all formulations. This agreement enables Biogen Idec to develop all Neublastin product opportunities and replaces a license and collaboration agreement from year 2000 under which Neublastin had been successfully brought into Phase I clinical development for the treatment of neuropathic pain.
NsGene will receive development milestone payments in accordance with the agreement from year 2000. The expanded agreement secures NsGene an upfront payment of USD 6 million, and an annual maintenance fee of USD 1.5 million until acceptance of the first regulatory filing for approval with respect to a Neublastin product. The maintenance fee will be paid in those years in which NsGene does not receive a development milestone. In addition, NsGene will receive increased royalties on future...See full deal structure in Biomedtracker
Partners: NsGene A/S
Pink Sheet Neurosearch
Additional information available to subscribers only: